pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Perjeta
drug
save

pertuzumab

Marketedupdated 6mo ago
by Genentech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagBreast Cancer9 co-mentions · 1 sources
  • tagOncology7 co-mentions · 1 sources
  • drugpertuzumab biosimilar2 co-mentions · 1 sources
  • drugPOHERDY2 co-mentions · 1 sources
  • tagHER22 co-mentions · 1 sources
  • tagApproval2 co-mentions · 1 sources
  • companyShanghai Henlius Biotech Inc1 co-mentions · 1 sources
  • companyXijing Hospital1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying pertuzumab

  • phase3A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trialactive not recruitingn=154
  • phase2Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)recruitingn=181
  • phase2T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAactive not recruitingn=164
  • phase3A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Canceractive not recruitingn=654
  • phase3Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutationactive not recruitingn=19
  • phase1To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Canceractive not recruitingn=200
  • phase2To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)completedn=147
  • phase3Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)active not recruitingn=1,157

News(8)

  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 9d ago
  • FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
    The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.
    biopharma_dive · 1mo ago
  • Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
    Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.
    onclive · 6mo ago
  • Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
    Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.
    onclive · 6mo ago
  • Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA
    Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
    onclive · 6mo ago
  • Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
    Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
    onclive · 6mo ago
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 6mo ago
  • Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
    Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
    onclive · 6mo ago
brand
Perjeta
generic
pertuzumab
indication
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 48m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?